Centogene NV, the crucial life science partner for data-driven answers in rare and neurological illnesses, has announced the discovery of a new small molecule alongside Evotec SE. The novel chemical has the potential to help individuals with type...
Chiesi Group, a pharmaceutical firm, declared the marking of a memorandum of understanding with Karolinska Institutet, a medical university. The understanding cements a responsibility between the two associations to team up on joint endeavors...
Mankind Pharma, a pharmaceutical firm, posted more than 65% in its final quarter profit, assisting areas of strength by request in its chronic drugs segment. The organization has also sanctioned a fundraising of up to 75 billion rupees or an...
Boehringer Ingelheim, a pharmaceutical firm, added that the domestic medication controller has endorsed a medication for Generalised Pustular Psoriasis (GPP) flares in grown-ups. The organization has secured an endorsement from the Central Drugs...
MediciNova, Inc., a biopharmaceutical firm, said that it has obtained a Notice of Allowance from the United States Patent and Trademark Office for a pending patent application for MN-166 (ibudilast) for the treatment of chlorine-induced acute...
Fortis Hospital Bannerghatta Road, recently achieved yet another significant clinical milestone with the successful completion of complex Robotic Kidney Transplant Surgeries for end-stage kidney disease
Hutchmed (China), a biopharmaceutical firm, declares that it has started a registrational stage III clinical preliminary of HMPL-306 in patients with changed isocitrate dehydrogenase (IDH) 1 or 2 backslid/refractory intense myeloid leukemia (AML)...
Instylla, Inc., a clinical-stage firm focused on creating fluid embolics for peripheral vascular embolotherapy, declared the completion of patient enlistment in the continuous Instylla HES Hypervascular Tumour Pivotal...
Moffitt Cancer Center, an incredibly famous cancer treatment and research center, and Fulgent Pharma, a nanobiotechnology firm, reported an essential organization pointed toward propelling cancer treatment through clinical turn of events and...
Fulcrum Therapeutics, Inc., a biotechnology firm declared that it has signed a collaboration and license agreement with Sanofi to develop and commercialize losmapimod, an oral small molecule being studied for the treatment of facioscapulohumeral...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
